Description
Finastelad 1 mg Driada Medical — finasteride from Driada Medical at 1 mg. Type II 5-alpha-reductase inhibitor. Reduces scalp and prostate DHT (70%+ reduction). Ineffective against DHT-derivative AAS.
Key Benefits
- 5α-reductase type-II inhibitor — suppresses scalp DHT
- Clinical standard for male-pattern hair loss
- On-cycle hair protection during testosterone-based protocols
- Not effective against DHT-derived AAS (trenbolone, masteron, oxandrolone)
- Sexual side-effects documented in a minority of users
- Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 1 mg/day for hair protection. Higher doses (5 mg) for BPH. Oral tablet, single daily dose.
How It Works
Selective 5α-reductase type-II inhibitor. Prevents conversion of testosterone to dihydrotestosterone (DHT) at scalp and prostate. Does not affect type-I isoform — whole-body DHT reduction around 70%.
Pharmacokinetics
Plasma half-life approximately 6 hours. Once-daily dosing. Scalp DHT reduction persists longer than plasma half-life suggests.
Potential Side Effects
Sexual side-effects (libido, ED) in a minority (2–8% in trials). Depression documented but rare. Does NOT protect against DHT-derivative AAS like tren, masteron, winstrol, anavar — those bypass 5α-reductase entirely.
Cycle & Stacking Guide
On-cycle daily with testosterone-based protocols if hair concerns exist. Pointless alongside DHT-derivative AAS. Consider dutasteride (type I + II inhibition) for more complete coverage if needed.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code; batch COAs available through the distributor.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.